I
246.34
3.60 (1.48%)
| Previous Close | 242.74 |
| Open | 243.57 |
| Volume | 1,208,336 |
| Avg. Volume (3M) | 850,420 |
| Market Cap | 17,340,497,920 |
| Price / Earnings (TTM) | 72.03 |
| Price / Earnings (Forward) | 36.76 |
| Price / Sales | 6.11 |
| Price / Book | 10.70 |
| 52 Weeks Range | |
| Earnings Date | 18 Feb 2026 |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Insulet Corporation | Bearish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | 1.13 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 435.00 (Canaccord Genuity, 76.59%) | Buy |
| Median | 340.00 (38.02%) | |
| Low | 274.00 (Barclays, 11.23%) | Sell |
| Average | 344.42 (39.82%) | |
| Total | 11 Buy, 1 Sell | |
| Avg. Price @ Call | 251.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 338.00 (37.21%) | Buy | 238.82 |
| 19 Feb 2026 | 345.00 (40.05%) | Buy | 249.10 | |
| Bernstein | 19 Feb 2026 | 330.00 (33.96%) | Buy | 249.10 |
| 09 Jan 2026 | 380.00 (54.26%) | Buy | 289.04 | |
| Canaccord Genuity | 19 Feb 2026 | 435.00 (76.59%) | Buy | 249.10 |
| Evercore ISI Group | 19 Feb 2026 | 340.00 (38.02%) | Buy | 249.10 |
| Goldman Sachs | 19 Feb 2026 | 326.00 (32.34%) | Buy | 249.10 |
| JP Morgan | 19 Feb 2026 | 340.00 (38.02%) | Buy | 249.10 |
| Leerink Partners | 19 Feb 2026 | 360.00 (46.14%) | Buy | 249.10 |
| Oppenheimer | 19 Feb 2026 | 300.00 (21.78%) | Buy | 249.10 |
| Truist Securities | 19 Feb 2026 | 360.00 (46.14%) | Buy | 249.10 |
| BTIG | 18 Feb 2026 | 380.00 (54.26%) | Buy | 258.07 |
| Stifel | 04 Feb 2026 | 350.00 (42.08%) | Buy | 251.24 |
| Barclays | 12 Jan 2026 | 274.00 (11.23%) | Sell | 278.55 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care |
| 09 Jan 2026 | Announcement | Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 |
| 06 Jan 2026 | Announcement | Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |